AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Hypertension

B Phase 2a ROCSTAR study is evaluating ROC-101, a potential first-in-class oral pan-ROCK inhibitor, in PAH and ILD-PH patients Clinical trial designed to evaluate ROC-101…
posteditor
posteditor
Articles: 16137

Other News